Last update: 2:32 PM
Comments
Loading...
Rocket Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RCKT | Benzinga
Rocket Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Rocket Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
B of A Securities
Chardan Capital
Cantor Fitzgerald
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Rocket Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/03/2025 | — | Leerink Partners | $9 → $7 | Maintains | Market Perform | |||
08/20/2025 | — | B of A Securities | $4 → $10 | Upgrade | Neutral → Buy | |||
08/20/2025 | — | Chardan Capital | $11 → $11 | Maintains | Buy | |||
08/11/2025 | — | Chardan Capital | $12 → $11 | Maintains | Buy | |||
08/08/2025 | — | Cantor Fitzgerald | $10 → $8 | Maintains | Overweight | |||
07/25/2025 | — | Canaccord Genuity | $11 → $10 | Maintains | Buy | |||
07/25/2025 | — | B of A Securities | $9 → $4 | Downgrade | Buy → Neutral | |||
07/24/2025 | — | Chardan Capital | $17 → $12 | Maintains | Buy | |||
07/24/2025 | — | Needham | — | Maintains | Hold | |||
06/17/2025 | — | UBS | $12 → $5 | Maintains | Buy | |||
06/03/2025 | — | Canaccord Genuity | $34 → $11 | Maintains | Buy | |||
05/28/2025 | — | B of A Securities | $32 → $9 | Maintains | Buy | |||
05/28/2025 | — | BMO Capital | $30 → $8 | Maintains | Outperform | |||
05/28/2025 | — | Scotiabank | $51 → $19 | Maintains | Sector Outperform | |||
05/28/2025 | — | Leerink Partners | $37 → $8 | Downgrade | Outperform → Market Perform | |||
05/28/2025 | — | Chardan Capital | $46 → $17 | Maintains | Buy | |||
05/28/2025 | — | Jefferies | $29 → $2.5 | Downgrade | Buy → Hold | |||
05/27/2025 | — | B of A Securities | $34 → $32 | Maintains | Buy | |||
05/27/2025 | — | Needham | $42 → $42 | Downgrade | Buy → Hold | |||
05/16/2025 | — | Cantor Fitzgerald | $20 → $30 | Maintains | Overweight | |||
05/16/2025 | — | Wedbush | $32 → $32 | Reiterates | Outperform → Outperform | |||
05/16/2025 | — | Chardan Capital | $45 → $46 | Maintains | Buy | |||
05/12/2025 | — | Scotiabank | $52 → $51 | Maintains | Sector Outperform | |||
05/12/2025 | — | Canaccord Genuity | $36 → $34 | Maintains | Buy | |||
05/09/2025 | — | Chardan Capital | $54 → $45 | Maintains | Buy | |||
05/09/2025 | — | JP Morgan | $45 → $44 | Maintains | Overweight | |||
05/09/2025 | — | Goldman Sachs | $15 → $13 | Maintains | Neutral | |||
04/09/2025 | — | Needham | $42 → $42 | Reiterates | Buy → Buy | |||
03/12/2025 | — | BMO Capital | → $50 | Initiates | → Outperform | |||
03/03/2025 | — | Scotiabank | $51 → $52 | Maintains | Sector Outperform | |||
03/03/2025 | — | Goldman Sachs | $29 → $15 | Maintains | Neutral | |||
03/03/2025 | — | Canaccord Genuity | $39 → $36 | Maintains | Buy | |||
02/28/2025 | — | Cantor Fitzgerald | $65 → $50 | Maintains | Overweight | |||
02/28/2025 | — | Chardan Capital | $62 → $54 | Maintains | Buy | |||
02/28/2025 | — | Needham | $52 → $42 | Maintains | Buy | |||
12/18/2024 | — | Jefferies | → $29 | Initiates | → Buy | |||
12/11/2024 | — | Leerink Partners | $44 → $40 | Maintains | Outperform | |||
11/19/2024 | — | Canaccord Genuity | $39 → $39 | Maintains | Buy | |||
11/19/2024 | — | Leerink Partners | $46 → $44 | Maintains | Outperform | |||
11/19/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
11/19/2024 | — | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
11/18/2024 | — | Chardan Capital | $62 → $62 | Maintains | Buy | |||
11/11/2024 | — | Chardan Capital | $62 → $62 | Maintains | Buy | |||
11/08/2024 | — | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
10/16/2024 | — | Scotiabank | → $50 | Initiates | → Sector Outperform | |||
09/30/2024 | — | Canaccord Genuity | $38 → $38 | Maintains | Buy | |||
09/17/2024 | — | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
08/06/2024 | — | JP Morgan | $50 → $54 | Maintains | Overweight | |||
08/06/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
08/06/2024 | — | Chardan Capital | $62 → $62 | Maintains | Buy | |||
08/06/2024 | — | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
07/03/2024 | — | Canaccord Genuity | $49 → $40 | Maintains | Buy | |||
06/28/2024 | — | Chardan Capital | $62 → $62 | Maintains | Buy | |||
06/28/2024 | — | Needham | $53 → $52 | Maintains | Buy | |||
05/07/2024 | — | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
04/10/2024 | — | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
04/02/2024 | — | Goldman Sachs | → $39 | Initiates | → Neutral | |||
03/01/2024 | — | UBS | $56 → $54 | Maintains | Buy | |||
02/27/2024 | — | JP Morgan | $55 → $50 | Maintains | Overweight | |||
02/27/2024 | — | Cantor Fitzgerald | $65 → $65 | Maintains | Overweight | |||
02/13/2024 | — | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
01/31/2024 | — | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
11/07/2023 | — | Needham | → $53 | Reiterates | Buy → Buy | |||
10/24/2023 | — | Cantor Fitzgerald | → $65 | Initiates | → Overweight | |||
09/13/2023 | — | Stifel | → $48 | Reiterates | Buy → Buy | |||
09/13/2023 | — | Needham | $60 → $53 | Maintains | Buy | |||
08/11/2023 | — | Canaccord Genuity | $49 → $47 | Maintains | Buy | |||
08/11/2023 | — | Chardan Capital | → $61 | Reiterates | Buy → Buy | |||
08/10/2023 | — | Needham | → $60 | Reiterates | Buy → Buy | |||
08/10/2023 | — | Stifel | $53 → $48 | Maintains | Buy | |||
05/23/2023 | — | Needham | → $60 | Reiterates | Buy → Buy | |||
05/08/2023 | — | Chardan Capital | $63 → $61 | Maintains | Buy | |||
05/05/2023 | — | Raymond James | $33 → $35 | Maintains | Outperform | |||
05/05/2023 | — | Needham | → $60 | Reiterates | → Buy | |||
04/19/2023 | — | Needham | → $60 | Reiterates | → Buy | |||
03/01/2023 | — | Chardan Capital | $65 → $63 | Reiterates | → Buy | |||
02/28/2023 | — | Needham | → $60 | Reiterates | → Buy | |||
02/01/2023 | — | Morgan Stanley | → $45 | Initiates | → Overweight | |||
01/23/2023 | — | SVB Leerink | $50 → $49 | Maintains | Outperform | |||
12/23/2022 | — | B of A Securities | $38 → $35 | Maintains | Buy | |||
12/22/2022 | — | SVB Leerink | $54 → $50 | Maintains | Outperform | |||
12/06/2022 | — | SVB Leerink | $56 → $54 | Maintains | Outperform | |||
11/08/2022 | — | Canaccord Genuity | → $53 | Initiates | → Buy | |||
11/07/2022 | — | Raymond James | $34 → $33 | Maintains | Outperform | |||
11/04/2022 | — | Needham | $62 → $60 | Maintains | Buy | |||
11/01/2022 | — | BTIG | → $35 | Initiates | → Buy |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT) stock?
The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Leerink Partners on October 3, 2025. The analyst firm set a price target for $7.00 expecting RCKT to rise to within 12 months (a possible 89.13% upside). 45 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Leerink Partners, and Rocket Pharmaceuticals maintained their market perform rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
The last upgrade for Rocket Pharmaceuticals Inc happened on August 20, 2025 when B of A Securities raised their price target to $10. B of A Securities previously had a neutral for Rocket Pharmaceuticals Inc.
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
The last downgrade for Rocket Pharmaceuticals Inc happened on July 25, 2025 when B of A Securities changed their price target from $9 to $4 for Rocket Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on October 3, 2025 so you should expect the next rating to be made available sometime around October 3, 2026.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $9.00 to $7.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $3.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
